Thermo Fisher Scientific Inc
NYSE:TMO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (4.8), the stock would be worth $581.07 (24% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.9 | $470.22 |
0%
|
| 3-Year Average | 4.8 | $581.07 |
+24%
|
| 5-Year Average | 5 | $604.29 |
+29%
|
| Industry Average | 5.1 | $614.7 |
+31%
|
| Country Average | 2.4 | $296.22 |
-37%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$174.6B
|
/ |
Mar 2026
$45.2B
|
= |
|
|
$174.6B
|
/ |
Dec 2026
$47.5B
|
= |
|
|
$174.6B
|
/ |
Dec 2027
$49.9B
|
= |
|
|
$174.6B
|
/ |
Dec 2028
$53.2B
|
= |
|
|
$174.6B
|
/ |
Dec 2029
$57.4B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.7B USD | 3.9 | 25.5 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
958.5B USD | 335.6 | 3 973.8 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.7B USD | 5.1 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 18.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
329.9B CNY | 7.3 | 17.3 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.1B CHF | 5.1 | -120.5 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.5B USD | 4.6 | 25.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.5B USD | 9.3 | 45.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27B USD | 1.7 | 19.9 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | 6.4 | 29.6 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
20.7B USD | 6.4 | 38.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Thermo Fisher Scientific Inc
Glance View
Thermo Fisher Scientific Inc. stands as a towering entity in the life sciences industry, intricately weaving together science, technology, and business to drive scientific progress and innovation. Founded through a merger of Thermo Electron and Fisher Scientific in 2006, the company has grown exponentially to become a formidable partner for researchers, academicians, and clinicians worldwide. Its business model is built around a broad portfolio of offerings, including laboratory instruments, analytical tools, and consumables, which are crucial for research and quality control. By emphasizing research and development, Thermo Fisher has consistently advanced its technologies, ensuring that its solutions remain indispensable to ventures in pharmaceuticals, biotechnology, and diagnostics. The strategic acquisition of complementary businesses has been a key facet of Thermo Fisher’s growth, fortifying its position across various scientific fields. In essence, the company thrives on understanding the increasingly complex demands of the scientific community. It generates revenue by capitalizing on its diverse product lineup, subscription-based services, and personalized solutions that cater to specific client needs—ranging from equipment used to perform intricate genomic sequencing to reagents required for advanced laboratory experiments. Thus, Thermo Fisher sustains its financial health through a combination of one-time sales and recurring revenue streams, a strategy that not only reflects its adaptability but also ensures long-term profitability and market leadership in the ever-evolving landscape of scientific research.